Recent Price Movement and Market Context
On 26 Nov 2025, Vivo Bio Tech . recorded its lowest price in the last year at Rs.29.21. This level represents a notable drop from its 52-week high of Rs.56.90, underscoring a substantial contraction in market value. Over the last ten days, the stock has delivered a cumulative return of -13.69%, underperforming its sector by 1.2% on the day of the new low.
The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a persistent bearish trend. This contrasts with the broader market, where the Sensex has shown resilience, closing at 85,070.93 points, up 0.57% on the day and approaching its own 52-week high of 85,801.70.
Long-Term Performance and Comparative Analysis
Over the past year, Vivo Bio Tech . has delivered a total return of -25.42%, significantly lagging behind the Sensex’s 6.34% gain during the same period. This underperformance extends beyond the last year, with the stock trailing the BSE500 index in each of the previous three annual periods. The persistent negative returns highlight challenges in maintaining investor confidence and market momentum.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Metrics Reflecting Current Challenges
Vivo Bio Tech .’s financial indicators over recent periods reveal subdued growth and profitability. The company’s net sales have shown a compound annual growth rate (CAGR) of -0.84% over the last five years, signalling a contraction in revenue generation. Profit after tax (PAT) for the latest six months stands at Rs.2.21 crore, reflecting a decline of 59.07% compared to the previous period.
Return on Capital Employed (ROCE) for the half-year is recorded at 7.95%, which is relatively low for the Pharmaceuticals & Biotechnology sector. Additionally, the debtors turnover ratio at 3.54 times indicates slower collection efficiency, which could impact liquidity management.
Debt Servicing and Profitability Considerations
The company’s ability to service its debt is under pressure, with an average EBIT to interest ratio of 1.84. This ratio suggests limited buffer to cover interest expenses from operating earnings. Furthermore, the average return on equity (ROE) of 6.60% points to modest profitability relative to shareholders’ funds, which may influence perceptions of capital efficiency.
Valuation and Market Position
Despite the challenges, Vivo Bio Tech . is trading at a valuation that some may consider attractive, with an enterprise value to capital employed ratio of 0.8. This indicates the stock is priced at a discount relative to its capital base. However, this valuation must be viewed in the context of the company’s recent profit decline of 45.2% over the past year and its ongoing underperformance against peers.
Why settle for Vivo Bio Tech .? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Shareholding and Sectoral Context
The majority of Vivo Bio Tech .’s shares are held by non-institutional investors, which may influence trading patterns and liquidity. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen mixed performance in recent months. While the broader market indices and mid-cap segments have shown gains, Vivo Bio Tech .’s stock has not mirrored this trend.
Summary of Key Price and Performance Indicators
To summarise, Vivo Bio Tech .’s stock has reached Rs.29.21, its lowest level in the past 52 weeks, following a sustained period of decline. The stock’s performance contrasts with the broader market’s upward movement, including the Sensex’s proximity to its own 52-week high. Financial metrics reveal subdued sales growth, declining profits, and modest returns on capital, alongside a valuation discount relative to capital employed.
These factors collectively illustrate the current market environment for Vivo Bio Tech ., highlighting the challenges faced by the company in maintaining its market position and financial momentum.
Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →
